# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Adam Maeder maintains Vicarious Surgical (NYSE:RBOT) with a Neutral, adjusts target to $12 from $30 (1-30...
Vicarious Surgical (NYSE:RBOT) reported quarterly losses of $(2.86) per share which missed the analyst consensus estimate of $(...
Morgan Stanley analyst Patrick Wood maintains Vicarious Surgical (NYSE:RBOT) with a Equal-Weight and lowers the price target...
Vicarious Surgical shares are trading lower by 20% during Tuesday's session. The company announced a 1-for-30 reverse stock...
The Company anticipates that the 1-for-30 reverse stock split will be effective as of 4:15 p.m. on June 12, 2024 and the Compan...